About Jeena Sikho Lifecare Ltd (JSLL)
Jeena Sikho Lifecare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JSLL and on the BSE under scrip code 544476. Its ISIN is INE0J5801029.
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.
Jeena Sikho Lifecare Limited is an integrated Ayurvedic healthcare company operating a dual model of hospitals/clinics (services) and an OTC/personal care products business, running a hub‑and‑spoke network across 23 states with 58 hospitals, 59 clinics/day‑care centres and several thousand beds operational and in development.
Q3 FY26 performance shows sharp operational momentum: Revenue at ₹221.7 crore (▲92% YoY, ▲17% QoQ), EBITDA ₹100.8 crore with a 45% margin and PAT ₹66.7 crore at a 30% margin, highlighting unusually high profitability for a healthcare chain driven by product margins and operating leverage in services.
Listed peers in Pharmaceuticals: Sun Pharma Advanced Research Company Ltd, Sanofi India Ltd, FDC Ltd, Supriya Lifescience Ltd, Senores Pharmaceuticals Ltd, Aarti Pharmalabs Ltd.
Valuation & Returns
10 Jul 2026At ₹592 a share on 10 Jul 2026, Jeena Sikho Lifecare Ltd (JSLL) was valued at a price-to-earnings ratio of 33.19x and a price-to-book of 58.49x on a book value of ₹10.12 per share as of Mar 2023. Solomo computes return on equity of 176.23% and return on capital employed of 245.04% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 33.19x
- P/B
- 58.49x
- EPS (TTM)
- ₹17.84
- Book value / share
- ₹10.12
- ROE
- 176.23%
- ROCE
- 245.04%
- ROA
- 146.79%
- Debt / equity
- 0.01x
- Dividend yield
- 0.19%
- 52-week range
- ₹108.2 – ₹289
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Jeena Sikho Lifecare Ltd (JSLL) reported revenue of ₹801 crore, net profit of ₹222 crore and earnings per share of ₹17.85. That compares with revenue of ₹469 crore and net profit of ₹80 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹216 crore and net profit ₹45 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 147 | 205 | 469 | 801 |
| Net profit (₹ cr) | 11 | 34 | 80 | 222 |
| EPS (₹) | 1.23 | 2.72 | 6.43 | 17.85 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 37.80% | 47.41% | 39.71% |
| Profit growth | 73.77% | 100.41% | 199.55% |
| Stock price CAGR | - | 101% | 6% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.62% of Jeena Sikho Lifecare Ltd (JSLL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.78% and domestic institutional investors (DII) hold 0.36%. Market capitalisation was ₹7,359 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2022.
Largest disclosed public shareholders in Jun 2026: SIXTEENTH STREET ASIAN GEMS FUND 4.2%, OREGANO LIFE PRIVATE LIMITED 2.95%, AJAY KUMAR AGGARWAL 1.68%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.62% | - | 4.78% | 0.36% | 36.38% |
| Mar 2026 | 63.62% | - | 6.17% | 0.46% | 36.38% |
| Dec 2025 | 63.62% | - | 6.31% | 0.11% | 36.38% |
| Sep 2025 | 63.61% | - | 6.59% | 0.15% | 36.39% |
| Mar 2025 | 63.53% | - | - | - | - |
| Sep 2024 | 65.84% | - | - | - | - |
| Mar 2024 | 67.91% | - | - | - | - |
| Sep 2023 | 67.91% | - | - | - | - |